| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.05.3579 |
| P8608 | Fatcat ID | release_wm4oap6pijew7m5xvyecj2f5m4 |
| P698 | PubMed publication ID | 16809731 |
| P50 | author | Joel Picus | Q92197943 |
| G. Kim Bigley | Q97579723 | ||
| Henry C Pitot | Q107054204 | ||
| Charles Erlichman | Q107069384 | ||
| Michelle R. Mahoney | Q112326955 | ||
| Cristine Allmer | Q114402710 | ||
| Ross C Donehower | Q114439526 | ||
| Tom R Fitch | Q117264222 | ||
| P2093 | author name string | James Thomas | |
| Philip A Philip | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3069-3074 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II study of erlotinib in patients with advanced biliary cancer | |
| P478 | volume | 24 |
| Q48126437 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer |
| Q84325484 | A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management |
| Q34611637 | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas |
| Q37719383 | A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. |
| Q40164640 | A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer |
| Q37639577 | A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers |
| Q33399656 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients |
| Q33411061 | A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma |
| Q79962521 | A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers |
| Q41652822 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study |
| Q37678436 | A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor |
| Q47118575 | Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma |
| Q38082318 | Advances in the management of biliary tract cancers |
| Q54557871 | An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. |
| Q37347275 | Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line |
| Q38811373 | Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway |
| Q34978321 | Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q64101426 | Biliary tract cancers: current knowledge, clinical candidates and future challenges |
| Q38017118 | Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options |
| Q36614800 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial |
| Q33392786 | Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. |
| Q37575602 | Changing the clinical picture of challenging tumors: tales becoming reality? |
| Q33977171 | Chemotherapy and targeted therapy for gall bladder cancer |
| Q51340875 | Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. |
| Q37983498 | Chemotherapy for the biliary tract cancers: moving toward improved survival time |
| Q42818294 | Chemotherapy in gallbladder carcinoma |
| Q35715498 | Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. |
| Q36962011 | Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives |
| Q34959174 | Cholangiocarcinoma: molecular pathways and therapeutic opportunities |
| Q38701620 | Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. |
| Q36614705 | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma |
| Q50738801 | Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. |
| Q37866791 | Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. |
| Q33723528 | Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report |
| Q35583920 | Current management of gallbladder carcinoma |
| Q57154668 | Current state of nonsurgical therapies for cholangiocarcinoma |
| Q37138732 | Current status of chemotherapy for the treatment of advanced biliary tract cancer |
| Q37161293 | Current therapy and future directions in biliary tract malignancies |
| Q37833005 | Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities |
| Q36623076 | Development of new cancer therapeutic agents targeting mitosis |
| Q26767120 | Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy |
| Q42995804 | Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q55381085 | EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. |
| Q33372792 | EGFR expression in gallbladder carcinoma in North America |
| Q33388581 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma |
| Q43237133 | Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study |
| Q33381056 | Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma |
| Q45363859 | Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. |
| Q36989921 | Emerging drugs for biliary cancer |
| Q51327505 | Emerging drugs for biliary cancer. |
| Q39227356 | Emerging molecular therapeutic targets for cholangiocarcinoma |
| Q45871350 | EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus |
| Q37613580 | Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report |
| Q54777001 | Erlotinib: applications in therapy and current status of research. |
| Q38707983 | Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma |
| Q36582547 | Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma |
| Q80605580 | Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer |
| Q33375557 | Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma |
| Q35840582 | Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma |
| Q90138085 | FOLFIRI as second-line treatment of metastatic biliary tract cancer patients |
| Q35924976 | Gallbladder cancer: expert consensus statement. |
| Q30317428 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. |
| Q53393758 | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. |
| Q33394065 | Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study |
| Q37794438 | Genetic abberations in gallbladder cancer |
| Q37765099 | Genetics of biliary tract cancers and emerging targeted therapies |
| Q34540948 | Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice |
| Q34104493 | Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q34588361 | Guidelines for chemotherapy of biliary tract and ampullary carcinomas |
| Q54478596 | HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. |
| Q33404756 | Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours |
| Q39137066 | Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. |
| Q38627950 | INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q48327823 | Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. |
| Q39186928 | Intrahepatic cholangiocarcinoma: current management and emerging therapies |
| Q27002547 | Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies |
| Q33775133 | L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation |
| Q34628852 | Markers of bile duct tumors |
| Q35150642 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer |
| Q35820533 | Molecular Targets in Biliary Carcinogenesis and Implications for Therapy |
| Q36488070 | Molecular genetics and targeted therapeutics in biliary tract carcinoma |
| Q28072275 | Molecular profiling of biliary tract cancer: a target rich disease |
| Q35023456 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers |
| Q35674607 | Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management |
| Q38130469 | Multidisciplinary approaches to intrahepatic cholangiocarcinoma |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q38160836 | New and emerging treatment options for biliary tract cancer |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q27010873 | Optimum chemotherapy for the management of advanced biliary tract cancer |
| Q100490609 | Overview of current targeted therapy in gallbladder cancer |
| Q33994406 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. |
| Q83969569 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness |
| Q37909373 | Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies |
| Q27016150 | Progression of targeted therapy in advanced cholangiocarcinoma |
| Q33395417 | Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer |
| Q38577917 | Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure |
| Q37316228 | Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. |
| Q34048813 | Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study |
| Q37351498 | Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma |
| Q37594373 | S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma |
| Q40860251 | Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. |
| Q92460033 | Second-line therapies in advanced biliary tract cancers |
| Q55223567 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. |
| Q37706763 | Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q41140456 | Surgery and chemotherapy for intrahepatic cholangiocarcinoma. |
| Q36758136 | Surgical resection of splenic metastasis from the adenosquamous gallbladder carcinoma: A case report. |
| Q93140863 | Systemic therapy for cholangiocarcinoma |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| Q26798443 | Targeted Therapy in Biliary Tract Cancers |
| Q37584590 | Targeted agents: how can we improve the outcome in biliary tract cancer? |
| Q36717905 | Targeted anti-mitotic therapies: can we improve on tubulin agents? |
| Q42635172 | Targeted medical therapy of biliary tract cancer: recent advances and future perspectives |
| Q37132750 | Targeted therapy for biliary tract cancer |
| Q37982650 | Targeted therapy for biliary tract cancers |
| Q37650623 | Targeted therapy in biliary tract cancer: 2009 update. |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q33750719 | Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas |
| Q52757760 | Targeting cholangiocarcinoma. |
| Q35000785 | Targeting metastatic upper gastrointestinal adenocarcinomas |
| Q28476545 | Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma |
| Q33388402 | The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma |
| Q39422598 | The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines |
| Q26751224 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| Q37261360 | The role of chemotherapy in biliary tract carcinoma |
| Q41988283 | The value of molecular biomarkers in biliary tract cancer in the era of targeted therapy. |
| Q33621529 | Therapeutic options for intrahepatic cholangiocarcinoma |
| Q37177871 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma |
| Q37169357 | c-Met targeted therapy of cholangiocarcinoma |
Search more.